Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
about
Clinical use and applications of histone deacetylase inhibitors in multiple myelomaCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaNew and emerging HDAC inhibitors for cancer treatmentPredicting response to epigenetic therapyDNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.Response to hydralazine-valproate in a patient with mycosis fungoidesHistone deacetylases, microRNA and leptin crosstalk in pancreatic cancer.Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significanceEpigenetic Signatures in Breast Cancer: Clinical PerspectiveTropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survivalNovel therapeutic agents for cutaneous T-Cell lymphoma.Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinomaThe antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.Dido3-dependent HDAC6 targeting controls cilium size.Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.Belinostat: clinical applications in solid tumors and lymphoma.HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.HDAC inhibitor-based therapies: can we interpret the code?Histone deacetylase inhibitors in hematological malignancies and solid tumors.Histone deacetylase 6 in health and disease.Epigenomic regulation of oncogenesis by chromatin remodeling.Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.HDACs and HDAC Inhibitors in Cancer Development and Therapy.Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.Spiro[chromane-2,4'-piperidine]-based histone deacetylase inhibitors with improved in vivo activity.
P2860
Q26745930-5C9516CD-7575-4282-9C48-BE5BB3EFC14FQ26851166-08696CB0-1A56-4BD9-AE40-A43F40373AB0Q27022413-8E1DFC13-D52F-4943-8F6F-6B564F1D3300Q27027751-E0B3329A-C659-40B5-A625-48AF34DA2FACQ30931932-64E0F5B8-2889-4C86-9C76-54E6A4927756Q33743913-6A5F6214-D4A2-4DE4-A132-A33F60AD734DQ33779854-F0316780-CDA6-476D-8ED5-4BC659410082Q33970364-0F6AD342-A66C-4331-AA61-B3F51C2B9041Q34095995-BA9C933D-8800-4EF9-8CAA-FAE00B587C12Q34363130-6AF7711E-B583-4D67-89E0-B9579852052DQ34399444-114D70D5-FD5A-435F-BEE8-7A1D2D17CD21Q34414452-A914FE93-1B5D-4851-B06C-7C4FCDB23290Q34434810-1F09076E-B22D-4C8D-ACFF-5FB1A24669A1Q35001132-06797EBC-EEBA-41B0-A672-4B8D5EDEEB35Q35235267-88613E85-37F4-40F7-AB88-6E03FFD52B73Q35821733-E09A3B9A-CFFB-46ED-881E-6CD9BD6C3B52Q36161365-986A788C-BE82-454C-8504-55E48D5DBF86Q36214527-720BF52A-BBDB-4DF9-9D4B-F168FFCBB571Q36343613-A27DA078-8537-4883-9A81-38E45F2CB892Q36926692-A74E21A0-CF99-45DA-B5EE-3DDF9D712FD7Q37062452-3D2E979F-B1AA-4645-8712-3FD81D540B9FQ37333839-E04E7AF0-8914-4AE5-9152-876E5FB19CABQ37680014-3451E38F-DF1C-4294-B185-EB83AA699C85Q37810272-8A58E900-73A4-4491-A896-EC386E1C0A55Q37951994-98D96624-C97D-43C2-8D53-577AD688F525Q37993586-14A1B7FB-EF01-415E-BCE0-887F4C62C30BQ38031633-980C942C-0A1E-4445-9B92-FB63C29C85D5Q38058971-750A47BD-B370-485D-A171-04861D37F1CEQ38344675-A8CD7B6A-D17C-409F-B390-48BE025C4FC6Q38357741-CD66EA3A-34B2-45AD-BEBC-0FBAFF267FE1Q38709544-A0E97F1A-0656-42DD-ADEB-CDDF631CF235Q38757938-46D52881-5535-4394-985F-CC978874F4D4Q38765451-44089B58-06CC-4C7A-B955-3DAEDACA4FF4Q38828275-554777E0-0E69-408D-867D-276C63998097Q38844615-53E10124-096D-4C7F-B455-8C31B490B5D0Q38896751-013F275F-959C-43AF-8DBF-90AA31477940Q38906678-006A7A06-0FE1-4DBD-A84C-06EFE816F805Q38947405-14E99FDB-F304-45B1-98E9-3EC3D884CAF0Q39214195-B91E5EA3-9884-435E-8E75-2F5E25A59758Q39392545-EFF89DE7-092D-4822-8FAC-08DFE368F494
P2860
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Prognostic significance of the ...... 4 in cutaneous T-cell lymphoma
@en
Prognostic significance of the ...... in cutaneous T-cell lymphoma.
@nl
type
label
Prognostic significance of the ...... 4 in cutaneous T-cell lymphoma
@en
Prognostic significance of the ...... in cutaneous T-cell lymphoma.
@nl
prefLabel
Prognostic significance of the ...... 4 in cutaneous T-cell lymphoma
@en
Prognostic significance of the ...... in cutaneous T-cell lymphoma.
@nl
P2093
P2860
P1433
P1476
Prognostic significance of the ...... 4 in cutaneous T-cell lymphoma
@en
P2093
E Ralfkiaer
Ib J Christensen
L M Gjerdrum
L Marquard
M Sehested
P B Jensen
P2860
P304
P356
10.1111/J.1365-2559.2008.03109.X
P577
2008-09-01T00:00:00Z